The T-DOT (Toronto Disparities, Overdose and Treatment) study is an ongoing prospective cohort of people who use drugs in Toronto that was started in 2018 (formerly OiSIS). T-DOT aims to evaluate harm reduction hubs, including supervised consumption sites (SCS), drug checking services, opioid agonist therapies (OAT) and the broader continuum of care for substance related issues on participant health, behavioural and social outcomes.
The CDPE is leading a study to evaluate the impact of safer opioid supply programs in Toronto, Ontario.
The Policy Impact Unit works in partnership with drug policy stakeholders – including people who use drugs, affected communities, civil society, and policymakers – to support the development of evidence- and rights-based drug policies in Canada and around the globe.
Supervised consumption sites (SCS) are evidence-based harm reduction services that save lives and connect people to care. Research from Canada and internationally shows that SCS are associated with reduced public drug use, with no consistent evidence of increased crime or public disorder.
Read more here.